WebDisclosure
COMMUNIQUÉ DE PRESSE

par Medartis Holding AG (isin : CH0386200239)

Basel, 11th June 2024   Medartis announces resignation of CEO Christoph Brönnimann

Medartis Holding AG / Key word(s): Personnel
Basel, 11th June 2024   Medartis announces resignation of CEO Christoph Brönnimann

11-Jun-2024 / 06:59 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this announcement.

Medartis announces that its CEO, Christoph Brönnimann, has decided to resign from his position and leave the company to pursue other opportunities. Christoph will continue to lead Medartis until a successor is onboarded. He will remain focused on the execution of the company’s strategy and committed to a smooth transition to the new leadership. The Board has initiated a search for his successor and will announce an appointment in due course.

<div> <p><span>Medartis Chairman, Marco Gadola, said: “Under Christoph’s leadership, Medartis has significantly accelerated its growth in its key markets, broadened the product portfolio and strengthened its standing with leading surgeons and hospitals worldwide. He has also expanded the capabilities of the organization and fostered an engaging culture, positioning the company for future success. This work will continue and growth remains our top priority.” </span></p> <p><span> </span></p> <p><span>Christoph added: “While this has been a difficult decision for me, I am proud of what we have accomplished together over the past five years. I will leave behind a talented executive team, a passionate organization and a company with huge potential for future growth.”</span></p> <p><span> </span></p> <p><span>The Board of Directors wholeheartedly thanks Christoph for his leadership, valuable contributions to Medartis and its success during his tenure, and wishes him all the best for his future endeavors.</span><br/><br/>  </p> </div> </div><div markup="footer"><p><span><span><span><b><span lang="EN-US">About Medartis</span></b></span><br/><span><span lang="EN-US"><span>Founded in 1997 and headquartered in Basel, Switzerland, Medartis (SIX Swiss Exchange: MED / ISIN CH0386200239) is one of the world's leading manufacturers and suppliers of medical devices for the surgical fixation of bone fractures in the upper and lower extremities and the craniomaxillofacial region. Medartis employs more than 830 people in 13 locations and its products are sold in more than 50 countries worldwide. Medartis is committed to providing surgeons and surgical staff with the most innovative titanium implants and instruments, as well as world-class service. For more information, please visit <a href="https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=ac1a9388ff4c0c3cae80f1661ff5fc2d&application_id=1921997&site_id=symex~~~af100301-a623-4c64-8f3d-90fc88eca9e6&application_name=news" style="text-decoration: none;">www.medartis.com</a>.</span> </span></span></span></span></p> </div><div markup="contact"><p><strong><span><span><span>Contact:</span></span></span></strong></p> <p><span><span><span>Medartis Holding AG<br/> Hochbergerstrasse 60E<br/> CH-4057 Basel</span></span></span></p> <p><span><span><span>Corporate Communications<br/> Investor contact: <a href="mailto:investor.relations@medartis.com" style="text-decoration: none;">investor.relations@medartis.com</a><br/> Media contact: <a href="mailto:corporate.communication@medartis.com" style="text-decoration: none;">corporate.communication@medartis.com</a><br/> +41 61 633 37 36 </span></span></span></p> </div></div> <br/><hr/>End of Inside Information<hr/></td> </tr></table><table cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" nowrap="nowrap">Language:</td> <td align="left" valign="top">English</td> </tr><tr><td align="left" valign="top" nowrap="nowrap">Company:</td> <td align="left" valign="top">Medartis Holding AG </td> </tr><tr><td align="left" valign="top"/> <td align="left" valign="top">Hochbergerstrasse 60E</td> </tr><tr><td align="left" valign="top"/> <td align="left" valign="top">4057 Basel</td> </tr><tr><td align="left" valign="top"/> <td align="left" valign="top">Switzerland</td> </tr><tr><td align="left" valign="top" nowrap="nowrap">Phone:</td> <td align="left" valign="top">+41 61 633 34 34</td> </tr><tr><td align="left" valign="top" nowrap="nowrap">Fax:</td> <td align="left" valign="top">+41 61 633 34 00</td> </tr><tr><td align="left" valign="top" nowrap="nowrap">E-mail:</td> <td align="left" valign="top">info@medartis.com</td> </tr><tr><td align="left" valign="top" nowrap="nowrap">Internet:</td> <td align="left" valign="top">www.medartis.com</td> </tr><tr><td align="left" valign="top" nowrap="nowrap">ISIN:</td> <td align="left" valign="top">CH0386200239</td> </tr><tr><td align="left" valign="top" nowrap="nowrap">Valor:</td> <td align="left" valign="top">38620023</td> </tr><tr><td align="left" valign="top">Listed:</td> <td align="left" valign="top">SIX Swiss Exchange</td> </tr><tr><td align="left" valign="top" nowrap="nowrap">EQS News ID:</td> <td align="left" valign="top">1921997</td> </tr></table><br/><table border="0" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" colspan="2"/> </tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" colspan="2"> </td> </tr><tr><td align="left" valign="top">End of Announcement</td> <td align="left" valign="top">EQS News Service</td> </tr></table><table border="0" width="600" cellpadding="0" cellspacing="0"><tr><td> <hr/></td> </tr></table><p> 1921997  11-Jun-2024 CET/CEST </p> <img src="https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1921997&application_name=news&site_id=symex~~~af100301-a623-4c64-8f3d-90fc88eca9e6" alt="fncls.ssp?fn=show_t_gif&application_id=1921997&application_name=news&site_id=symex~~~af100301-a623-4c64-8f3d-90fc88eca9e6" width="0" height="0" border="0"/>
Resignation CEO Successor Transition Medartis Holding AG
Voir toutes les actualités de Medartis Holding AG